Sun Pharmaceutical Industries Ltd. Share Price

Sun Pharmaceutical Industries has informed that the company and certain of its subsidiaries have been defendants in antitrust litigation in the United States relating to a 2008 patent litigation settlement agreement with Pfizer concerning generic Lipitor (Atorvastatin). Plaintiffs alleged that the settlement unlawfully delayed generic competition for Lipitor and that absent the unlawful settlement, Lipitor would have entered the market earlier than it did. The matter has been disclosed from time to time in the Company's financial statements. The United States Court of Appeals for the Third Circuit has affirmed the order of the United States District Court granting summary judgment in its entirety in favour of the Company and its subsidiaries. The Appellate Court has also affirmed the District Court's orders denying class certification as to the plaintiffs. This decision represents a significant favourable development for the Company and its subsidiaries in the matter, and brings the litigation substantially to a close, subject to any further remedies that may be available to the plaintiffs under applicable law.

The above information is a part of company’s filings submitted to BSE.  

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma receives approval to manufacture and market generic semaglutide in South Africa,’ which shall be released after this intimation.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of SEBI Listing Regulations Acutaas Chemicals has informed that it enclosed a copy of Press Release dated August 28, 2026 titled as ‘Acutaas Chemicals’ step-down subsidiary Indichem inaugurates Semiconductor Materials Plant at Gongju, The Republic of Korea’. The Press Release shall also be available on the website of the company at www.acutaas.com.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aanjaay Industries has informed that a meeting of the Board of Directors of the Company is scheduled to be held on 02nd September 2026 at the Corporate Office of the Company situated at Chennai, to consider and approve the following business: 1. To approve Director’s Report and Corporate Governance Report for the financial year ended 31st March 2026. 2. To approve closure of Register of Members and Share Transfer Books of the Company for Annual General Meeting (AGM) purpose. 3. To approve the Cut-off date to record the entitlement of shareholders to cast their votes for the Annual General Meeting (AGM). 4. To fix the Date, Time and Venue to convene the Annual General meeting of the Company & the draft Notice calling the Annual General Meeting (AGM). 5. To consider and approve appointment of scrutinizer for Annual General Meeting (AGM) purpose. 6. To consider and recommend the re-appointment of Kuniamuthur Nanjappan Anand (DIN: 03230186), Director of the Company, who retires by rotation at the ensuing Annual General Meeting 7. To consider and approve the appointment of Internal Auditors of the Company for the financial year 2026-2027. 8. To recommend the appointment of Moonam Kapoor (DIN: 09278005) as Director of the Company. 9. To recommend the appointment of Secretarial Auditor of the Company for the financial year 2026-2027 to 2030-2031. 10. Any other agenda with permission of chair.

The above information is a part of company’s filings submitted to BSE.